Literature DB >> 25115865

Pre-operative opioid analgesia reduces clinical success of laparoscopic gastric electrical stimulation placement in patients with gastroparesis.

Mena Boules1, Hideharu Shimizu, Andrea Zelisko, Kevin El-Hayek, Maged K Rizk, Matthew Kroh.   

Abstract

INTRODUCTION: Gastroparesis is a common chronic and costly disorder for which medical therapy is often unsuccessful. Gastric electrical stimulation (GES) has been used to treat refractory cases, however, response is variable and difficult to predict. This study aims to assess whether pre-operative opioid analgesics (OA) use affects clinical success of GES.
METHODS: Records of 128 patients who underwent laparoscopic GES placement from March 2001 to September 2012 were analyzed retrospectively. Data collected included demographics, surgical outcomes, and clinical parameters. Pre- and post-operative opioid analgesic dosing (No = 0 morphine equivalents (ME)/day, Low = 0-40 ME/day, Mid = 41-80 ME/day, High >80 ME/day), as well as clinical symptom assessment was collected for up to 3 years post-operatively. Clinical success was defined as (1) OA reduction of >50 %, (2) maintenance of weight, or (3) symptom improvement. Descriptive statistics were computed for all factors. A p < 0.05 was considered statistically significant.
RESULTS: Fifty-three patients were on OA pre-operatively compared to 69 patients who were not. Patients not on OA pre-operatively were less likely than those on OA pre-op group to be on OA post-operatively (p = 0.005); however, there were no differences in weight or symptom improvement. Sub-group analysis of the 53 patients on OA demonstrated significant improvement in clinical symptoms in the low-morphine cohort compared to the mid-morphine cohort (p = 0.02), and OA dosing post-operatively in the low-morphine cohort diminished significantly compared to mid- and high-morphine cohort (p = 0.032). There was no significant difference in weight.
CONCLUSION: OA dosing pre-operatively significantly affects clinical success of GES placement. Criteria for offering GES implantation may need to take OA dosing into consideration.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25115865     DOI: 10.1007/s00464-014-3754-9

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  18 in total

1.  Burst ketamine to reverse opioid tolerance in cancer pain.

Authors:  Sebastiano Mercadante; Patrizia Villari; Patrizia Ferrera
Journal:  J Pain Symptom Manage       Date:  2003-04       Impact factor: 3.612

Review 2.  Glia: novel counter-regulators of opioid analgesia.

Authors:  Linda R Watkins; Mark R Hutchinson; Ian N Johnston; Steven F Maier
Journal:  Trends Neurosci       Date:  2005-10-24       Impact factor: 13.837

Review 3.  Opioid-induced bowel dysfunction.

Authors:  Gyanprakash A Ketwaroo; Vivian Cheng; Anthony Lembo
Journal:  Curr Gastroenterol Rep       Date:  2013-09

Review 4.  Hyperalgesia and opioid switching.

Authors:  Sebastiano Mercadante; Edoardo Arcuri
Journal:  Am J Hosp Palliat Care       Date:  2005 Jul-Aug       Impact factor: 2.500

Review 5.  Opioid-induced constipation: challenges and therapeutic opportunities.

Authors:  Michael Camilleri
Journal:  Am J Gastroenterol       Date:  2011-02-22       Impact factor: 10.864

6.  Opioids and abnormal pain perception: New evidence from a study of chronic opioid addicts and healthy subjects.

Authors:  Dorit Pud; Doron Cohen; Eli Lawental; Elon Eisenberg
Journal:  Drug Alcohol Depend       Date:  2005-10-17       Impact factor: 4.492

7.  Laparoscopic gastric electrical stimulation for medically refractory diabetic and idiopathic gastroparesis.

Authors:  P Timratana; K El-Hayek; H Shimizu; M Kroh; B Chand
Journal:  J Gastrointest Surg       Date:  2013-01-04       Impact factor: 3.452

8.  The narcotic bowel syndrome: clinical features, pathophysiology, and management.

Authors:  David M S Grunkemeier; Joseph E Cassara; Christine B Dalton; Douglas A Drossman
Journal:  Clin Gastroenterol Hepatol       Date:  2007-10       Impact factor: 11.382

Review 9.  Opioid-induced bowel dysfunction: pathophysiology and management.

Authors:  Christina Brock; Søren Schou Olesen; Anne Estrup Olesen; Jens Brøndum Frøkjaer; Trine Andresen; Asbjørn Mohr Drewes
Journal:  Drugs       Date:  2012-10-01       Impact factor: 9.546

10.  Altered rectal sensory response induced by balloon distention in patients with functional abdominal pain syndrome.

Authors:  Tsukasa Nozu; Miwako Kudaira
Journal:  Biopsychosoc Med       Date:  2009-11-20
View more
  3 in total

1.  Per oral endoscopic pyloromyotomy for refractory gastroparesis: initial results from a single institution.

Authors:  John H Rodriguez; Ivy N Haskins; Andrew T Strong; Ryan L Plescia; Matthew T Allemang; Robert S Butler; Michael S Cline; Kevin El-Hayek; Jeffrey L Ponsky; Matthew D Kroh
Journal:  Surg Endosc       Date:  2017-05-31       Impact factor: 4.584

Review 2.  Electroceuticals in the Gastrointestinal Tract.

Authors:  Khalil B Ramadi; Shriya S Srinivasan; Giovanni Traverso
Journal:  Trends Pharmacol Sci       Date:  2020-10-27       Impact factor: 14.819

Review 3.  Gastric Electrical Stimulation for Gastroparesis and Chronic Unexplained Nausea and Vomiting.

Authors:  John M Wo; Thomas V Nowak; Shamaila Waseem; Matthew P Ward
Journal:  Curr Treat Options Gastroenterol       Date:  2016-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.